GSA Capital Partners LLP trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 13.1% in the second quarter, HoldingsChannel.com reports. The fund owned 18,377 shares of the biopharmaceutical company’s stock after selling 2,770 shares during the quarter. GSA Capital Partners LLP’s holdings in Gilead Sciences were worth $1,242,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GW Henssler & Associates Ltd. raised its holdings in shares of Gilead Sciences by 0.9% in the second quarter. GW Henssler & Associates Ltd. now owns 182,157 shares of the biopharmaceutical company’s stock worth $12,307,000 after acquiring an additional 1,708 shares during the last quarter. Centric Wealth Management purchased a new stake in shares of Gilead Sciences in the second quarter valued at $216,000. Regentatlantic Capital LLC grew its position in shares of Gilead Sciences by 26.4% in the first quarter. Regentatlantic Capital LLC now owns 42,596 shares of the biopharmaceutical company’s stock valued at $2,769,000 after purchasing an additional 8,886 shares during the period. Close Asset Management Ltd grew its position in shares of Gilead Sciences by 170.6% in the second quarter. Close Asset Management Ltd now owns 8,200 shares of the biopharmaceutical company’s stock valued at $554,000 after purchasing an additional 5,170 shares during the period. Finally, Private Trust Co. NA purchased a new stake in shares of Gilead Sciences in the second quarter valued at $203,000. 78.78% of the stock is owned by institutional investors.
In other news, EVP Brett A. Pletcher sold 608 shares of the company’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $64.35, for a total value of $39,124.80. Following the completion of the sale, the executive vice president now owns 27,198 shares of the company’s stock, valued at $1,750,191.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Brett A. Pletcher sold 7,200 shares of the company’s stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $65.07, for a total value of $468,504.00. Following the completion of the sale, the executive vice president now directly owns 34,398 shares of the company’s stock, valued at approximately $2,238,277.86. The disclosure for this sale can be found here. In the last three months, insiders have sold 13,624 shares of company stock valued at $907,479. 0.20% of the stock is owned by company insiders.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.68 by $0.14. Gilead Sciences had a return on equity of 37.12% and a net margin of 26.64%. The firm had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.54 billion. During the same quarter in the previous year, the business earned $1.91 earnings per share. The firm’s quarterly revenue was down 2.8% compared to the same quarter last year. On average, equities research analysts predict that Gilead Sciences, Inc. will post 6.65 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.03%. The ex-dividend date is Thursday, September 12th. Gilead Sciences’s dividend payout ratio (DPR) is presently 40.98%.
A number of brokerages have recently commented on GILD. JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $85.00 price objective on shares of Gilead Sciences in a research report on Wednesday, July 31st. Maxim Group set a $84.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, July 31st. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Monday, July 15th. Mizuho set a $88.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research report on Monday, July 15th. Finally, Wells Fargo & Co raised Gilead Sciences from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $68.00 to $88.00 in a research report on Monday, July 15th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $82.29.
Gilead Sciences Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Story: Why does a company issue an IPO?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.